Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease

Area of Science:

• Hepatology
• Biomarker Discovery
• Diagnostic Imaging

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide.
• MASLD progression can lead to severe outcomes like cirrhosis and hepatocellular carcinoma.
• Current diagnostic methods, including liver biopsy, have significant limitations.

Purpose of the Study:

• To comprehensively review the utility of blood-based and imaging biomarkers for MASLD.
• To discuss their roles in diagnosis, staging, prognosis, and management.
• To highlight non-invasive alternatives to liver biopsy.

Main Methods:

• Literature review of studies on blood-based biomarkers for MASLD.
• Analysis of research on imaging techniques for MASLD assessment.
• Synthesis of evidence on biomarker performance in diagnosis and prognosis.

Main Results:

• Various blood tests show promise in detecting liver steatosis and inflammation.
• Imaging modalities like ultrasound and MRI offer valuable insights into MASLD severity.
• Biomarkers can aid in risk stratification and monitoring treatment response.

Conclusions:

• Non-invasive biomarkers are crucial for addressing the MASLD epidemic.
• Blood-based and imaging markers offer a viable alternative to liver biopsy.
• Further research is needed to validate and implement these tools in clinical practice.